annual report

Good to see this statement on p3:

As an aside, Actavis has confirmed support for our MOXDUO FDA strategy and are fully engaged with our efforts to address the FDA’s concerns.

I mean every little bit helps but what realistically would Actavis be doing to support the efforts?

Another high point, p4:

The Company retains $23 million in cash reserves at 30 June 2012.


And finally, also p4:


The Board and I are optimistic about the Company’s future as we prepare totransition from a clinical stage company to a commercial entity with revenues.
In fact, changing regulations for acute pain opioids are creating even greater market opportunity for our Dual Opioid product portfolio. For example, the FDA
are requiring that all combination paracetamol (acetaminophen) / opioid acute pain products containing more than 325mg of paracetamol are to be removed
from the market by January 2014,....

A nice summary in the Chairman's Letter - positive.

I'm waiting for the shock of the initial stumbling block in missing approval to wear off, to see a reignited interest in QRX...and the fact that Orbis increased their shareholding by 1.6M between Sept 11 and 20 Sept 12 - a lot of which came in the days after or on the June 27 fall. (See the Form 604 Change in Substantial Holding of 24/9 page 4).